{"title": "Hepatitis Biomarker Collection 3 \u2014 Cylindrical Hepatitis And Liver Health", "authors": "Emily Johnson Robert Lee Jared Vincent Brandi Reyes Robert Thompson", "published_date": "01-29-2020", "affiliation": "University of California-Berkeley, School of Environmental Studies", "text": "Analyzing liver enzymes is an essential method for developing a clear picture of complex viral infection, as most viral types that cause viral hepatitis can damage liver function. A continuous analysis of the human liver, with particular focus on the liver, during treatment with antiviral drugs can be used to develop human hepatitis drugs with regard to molecular targets. The molecular mechanism of hepatitis with which human liver is being protected from toxicities is a crucial fact for developing effective antiviral drugs for hepatitis B, hepatitis C, and liver diseases. Some drugs target this crucial and important biological target of hepatitis by modifying the protein structure at the cellular level. Unfortunately, there is limited information about liver enzymes, enzymes, and enzyme bases at the molecular level.<p>In this article, we have presented the results of liver enzyme analyses of active human hepatitis candidates through LiFe Biomarker 3 at the level of polysaccharide insoluble viruses (called polysaccharide viral isoforms). The analyses revealed that stable RNA monosporides in polysaccharide viral isoforms are able to elicit nucleoacryption and crosslinking. By studying sites of nucleoacryption in polysaccharide viral isoforms, it was possible to formulate a liver enzyme\u2013RNA mediated biomarker. By adapting this biomarker, novel oral hepatitis drugs with this biomarker could be developed to treat human liver diseases.<p>The analysis of hepatofoxins (LHB) was a requirement for an accurate hepatitis B therapeutic antibody. By using LiFe biomarker 3, the synthetic level of LHB from polysaccharide viruses called hepfafaces cells can be measured in the liver. The analysis also showed that high levels of liver enzymes are obtained at a very stable level in hepatofoxins. The hepatofoxins that are completely soluble in the polysaccharide viruses can be utilized by viral antiviral drug developers. This explains the benefit of developing inhibitors of hepatitis B inhibition-cell Division Lines or HIV interferon antibodies.<p>B \u2013 R \u2013 I \u2013 DNA \u2013 CEH. LiFe Biomarker: Hepatitis Biomarker Collection 3 (LiFe Biomarker 3). Materials: Hyde Park Institute for Biomolecular Sciences at Southwestern University, Houston, TX. Laboratory: Technology Products for Drug Discovery (TPFD). Materials definition: Ling Pham"}